Voltage-gated L-type and T-type calcium channels (LTCC/TTCC)

Voltage-gated L-type and T-type calcium channels are essential transmembrane proteins that facilitate the influx of calcium ions into cells upon membrane depolarization (StatPearls, 2023). L-type channels (Cav1 family) are high-voltage activated and are primarily responsible for excitation-contraction coupling in cardiac and smooth muscle, as well as regulating gene expression and hormone secretion (UniProt, 2024). T-type channels (Cav3 family) are low-voltage activated and play a crucial role in pacemaking activity in the heart and rhythmic firing in the central nervous system (NCBI, 2022). These channels are significant therapeutic targets; L-type blockers like amlodipine are standard treatments for hypertension and angina, while T-type blockers like ethosuximide are used for absence seizures (PubMed, 2021). Dual L-type and T-type blockers, such as mibefradil, were developed to provide comprehensive cardiovascular control, though safety concerns regarding drug-drug interactions limited their clinical use (PubChem, 2024). Inhibition of these channels leads to vasodilation, reduced heart rate, and decreased neuronal excitability, making them versatile targets for both cardiovascular and neurological conditions. Research continues into selective T-type blockers for chronic pain and epilepsy to avoid the cardiovascular side effects associated with L-type inhibition.

Other names

Cav1 and Cav3 channelsHigh-voltage activated and low-voltage activated calcium channelsL-type and T-type Ca2+ channels

Inhibition of calcium ion influx through the channel pore by binding to the alpha-1 subunit, leading to vasodilation and reduced cardiac excitability (StatPearls, 2023).